

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Operations**  
(In thousands, except per share data)  
(Unaudited)

	Three Months Ended		Year Ended	
	January 1, 2022	January 2, 2021	January 1, 2022	January 2, 2021
Revenues	\$ 208,680	\$ 145,829	\$ 720,860	\$ 510,928
Cost of revenues	80,849	61,894	295,468	216,083
Gross profit	127,831	83,935	425,392	294,845
Operating expenses:				
Research and development	71,705	60,554	273,208	235,185
Selling, general and administrative	53,487	41,792	185,022	166,748
Operating expenses	125,192	102,346	458,230	401,933
Operating income (loss)	2,639	(18,411)	(32,838)	(107,088)
Other income (expense):				
Interest income and other, net	2,595	1,206	5,696	9,027
Interest expense	(6,628)	(8,219)	(31,033)	(34,142)
Loss from continuing operations before income taxes	(1,394)	(25,424)	(58,175)	(132,203)
Provision (benefit) for income taxes	884	(2,702)	13,427	(14,602)
Equity-method earnings	7,791	1,375	13,728	2,116
Income (loss) from continuing operations	5,513	(21,347)	(57,874)	(115,485)
Income (loss) from discontinued operations, net of income taxes	(8,611)	30,295	2,175,273	128,016
Net income (loss)	\$ (3,098)	\$ 8,948	\$ 2,117,399	\$ 12,531
Basic earnings (loss) per share:				
Continuing operations	\$ 0.14	\$ (0.49)	\$ (1.35)	\$ (2.64)
Net income	\$ (0.08)	\$ 0.20	\$ 49.44	\$ 0.29
Diluted earnings (loss) per share:				
Continuing operations	\$ 0.13	\$ (0.49)	\$ (1.35)	\$ (2.64)
Net income	\$ (0.08)	\$ 0.20	\$ 47.78	\$ 0.28
Weighted-average common shares outstanding:				
Basic	38,965	43,895	42,830	43,775
Diluted	41,031	44,729	44,315	44,372

**Silicon Laboratories Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except per share data)  
(Unaudited)

	<b>January 1, 2022</b>	<b>January 2, 2021</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$1,074,623	\$ 202,720
Short-term investments	964,582	521,963
Accounts receivable, net	98,313	95,169
Inventories	49,307	47,861
Prepaid expenses and other current assets	51,748	87,103
Current assets of discontinued operations	--	21,005
Total current assets	2,238,573	975,821
Property and equipment, net	146,516	135,803
Goodwill	376,389	376,389
Other intangible assets, net	118,978	163,483
Other assets, net	77,839	76,675
Non-current assets of discontinued operations	--	265,316
Total assets	\$2,958,295	\$1,993,487
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 47,327	\$ 54,949
Current portion of convertible debt, net	450,599	134,480
Deferred revenue and returns liability	13,849	12,986
Other current liabilities	157,052	81,650
Current liabilities of discontinued operations	--	433
Total current liabilities	668,827	284,498
Convertible debt, net	--	428,945
Other non-current liabilities	77,044	79,752
Non-current liabilities of discontinued operations	--	451
Total liabilities	745,871	793,646
Commitments and contingencies		
Stockholders' equity:		
Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued	--	--
Common stock – \$0.0001 par value; 250,000 shares authorized; 38,481 and 43,925 shares issued and outstanding at January 1, 2022 and January 2, 2021, respectively	4	4
Additional paid-in capital	--	204,359
Retained earnings	2,214,839	993,664
Accumulated other comprehensive income (loss)	(2,419)	1,814
Total stockholders' equity	2,212,424	1,199,841
Total liabilities and stockholders' equity	\$2,958,295	\$1,993,487

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

	<b>Year Ended</b>	
	<b>January 1, 2022</b>	<b>January 2, 2021</b>
<b>Operating Activities</b>		
Net income	\$2,117,399	\$ 12,531
Adjustments to reconcile net income to cash provided by (used in) operating activities of continuing operations:		
Income from discontinued operations, net of income taxes	(2,175,273)	(128,016)
Depreciation of property and equipment	18,051	16,267
Amortization of other intangible assets	44,505	42,569
Amortization of debt discount and debt issuance costs	22,767	21,433
Loss on extinguishment of convertible debt	3,370	4,060
Stock-based compensation expense	56,842	49,454
Equity-method earnings	(13,728)	(2,116)
Deferred income taxes	(3,414)	(6,533)
Changes in operating assets and liabilities:		
Accounts receivable	(3,144)	(17,612)
Inventories	(1,510)	9,148
Prepaid expenses and other assets	44,664	(50,664)
Accounts payable	(7,704)	15,263
Other current liabilities and income taxes	2,109	3,215
Deferred revenue and returns liability	863	(6,694)
Other non-current liabilities	(14,599)	28,856
Net cash provided by (used in) operating activities of continuing operations	91,198	(8,839)
<b>Investing Activities</b>		
Purchases of marketable securities	(1,541,971)	(519,567)
Sales and maturities of marketable securities	1,095,041	497,357
Purchases of property and equipment	(28,577)	(18,088)
Purchases of other assets	(1,158)	(1,210)
Acquisitions of businesses, net of cash acquired	--	(316,809)
Net cash used in investing activities of continuing operations	(476,665)	(358,317)
<b>Financing Activities</b>		
Proceeds from issuance of debt	--	845,000
Payments on debt	(140,572)	(624,737)
Repurchases of common stock	(1,150,044)	(16,287)
Payment of taxes withheld for vested stock awards	(22,239)	(18,124)
Proceeds from the issuance of common stock	14,183	15,015
Net cash provided by (used in) financing activities of continuing operations	(1,298,672)	200,867
<b>Discontinued Operations</b>		
Operating activities	(191,642)	144,557
Investing activities	2,747,684	(2,694)
Net cash provided by discontinued operations	2,556,042	141,863
Increase (decrease) in cash and cash equivalents	871,903	(24,426)
Cash and cash equivalents at beginning of period	202,720	227,146
Cash and cash equivalents at end of period	<u>\$1,074,623</u>	<u>\$202,720</u>

## Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

### Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

Non-GAAP Income Statement Items	Three Months Ended January 1, 2022						
	GAAP Measure	GAAP Percent of Revenue	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs	Non- GAAP Measure	Non-GAAP Percent of Revenue
Revenues	\$208,680						
Gross profit	127,831	61.3%	\$267	\$ --	\$ --	\$128,098	61.4%
Research and development	71,705	34.4%	6,796	7,753	--	57,156	27.4%
Selling, general and administrative	53,487	25.6%	12,863	2,781	939	36,904	17.7%
Operating expenses	125,192	60.0%	19,659	10,534	939	94,060	45.1%
Operating income	2,639	1.3%	19,926	10,534	939	34,038	16.3%

Non-GAAP Earnings Per Share and Tax Rate – Continuing Operations	Three Months Ended January 1, 2022									
	GAAP Measure	GAAP Tax Percentage Rate	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs	Investment Fair Value Adjustments	Interest Expense Adjustments	Income Tax Adjustments	Non- GAAP Measure	Non-GAAP Tax Percentage Rate
Income from continuing operations before income taxes	\$6,397		\$19,926	\$10,534	\$939	\$(7,856)	\$5,106	\$ --	\$35,046	
Provision for income taxes	884	13.8%						2,670	3,554	10.1%
Income from continuing operations	\$5,513								\$31,492	
Diluted shares outstanding	41,031								41,031	
Diluted earnings per share	\$ 0.13								\$ 0.77	

**Unaudited Forward-Looking Statements Regarding Business Outlook\*\***  
**(In millions, except per share data)**

<b>Business Outlook</b>	<b>Three Months Ending April 2, 2022</b>		
	<b>GAAP Measure</b>	<b>Non-GAAP Adjustments*</b>	<b>Non-GAAP Measure</b>
Gross margin	63%	0%	63%
Operating expenses	\$128	\$(23)	\$105
Effective tax rate	37%	(7)%	30%
Diluted earnings per share - low	\$ 0.15	\$ 0.43	\$ 0.58
Diluted earnings per share - high	\$ 0.25	\$ 0.43	\$ 0.68

\* Non-GAAP adjustments include the following estimates: stock compensation expense of \$13 million, intangible asset amortization of \$10 million, and the associated tax impact from the aforementioned items.

\*\* These financial schedules contain forward-looking statements based on Silicon Labs' current expectations. The words "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the effect of the Skyworks transaction on the ability of Silicon Labs to retain and hire key personnel and maintain relationships with its customers, suppliers, advertisers, partners and others with whom it does business, or on its operating results and businesses generally; risks associated with the disruption of management's attention from ongoing business operations due to such transaction; the timing and scope of anticipated share repurchases, and/or dividends; the impact of COVID-19 on the U.S. and global economy, including the restrictions on travel and transportation and other actions taken by governmental authorities and disruptions to the business of our customers or our global supply chain that have occurred or may occur in the future, the ongoing impact of COVID-19 on our employees and our ability to provide services to our customers and respond to their needs; risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; debt-related risks; capital-raising risks; the competitive and cyclical nature of the semiconductor industry; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. The level of share repurchases and/or dividends depends on market conditions and the level of other uses of cash. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. References in these financial schedules to Silicon Labs shall mean Silicon Laboratories Inc.